|
시장보고서
상품코드
1873405
세계의 췌장암 진단 시장 : 시장 점유율과 순위, 전체 판매 및 수요 예측(2025-2031년)Pancreatic Cancer Diagnostic - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031 |
||||||
QYResearch
세계의 췌장암 진단 시장 규모는 2024년에 65억 7,200만 달러로 추정되며, 2025년부터 2031년까지 예측 기간 동안 CAGR 7.3%로 성장하여 2031년까지 106억 9,000만 달러로 확대될 것으로 예측됩니다.
췌장암 진단이란 췌장암을 다양한 단계에서 발견하고 확인하는 데 사용되는 방법 및 기술을 말합니다. 여기에는 CT, MRI, 내시경 초음파 검사(EUS) 등의 영상 진단 기술뿐만 아니라 바이오마커 검사(예 : CA 19-9), 유전자 검사, 조직 생검 등의 분자진단이 포함됩니다. 초기에는 무증상이기 때문에 조기 발견이 어렵지만, 정확한 진단 도구는 적절한 치료와 생존율 향상에 필수적입니다.
췌장암 진단 시장은 전 세계적으로 췌장암 발병률의 증가와 조기 및 정확한 진단에 대한 긴급한 요구로 인해 성장하고 있습니다. 췌장암은 무증상으로 진행되기 때문에 진행된 단계에서 진단되는 경우가 많아 분자 바이오마커(예 : CA 19-9, KRAS 변이), 액체 생검, 차세대 염기서열분석(NGS), AI 지원 영상 진단 툴 등 첨단 진단 솔루션에 대한 수요가 증가하고 있습니다. 암 연구에 대한 정부 자금 지원과 정밀 종양학 이니셔티브의 부상도 혁신적인 진단 플랫폼의 개발과 보급을 촉진하고 있습니다.
기술 발전에도 불구하고 시장은 심각한 도전에 직면해 있습니다. 췌장암의 조기발견은 특이적인 증상의 부재와 현존하는 바이오마커의 민감도-특이성의 한계로 인해 여전히 어려운 실정입니다. 유전자 염기서열 분석, 영상 진단 등 고도의 진단 기법에 따른 높은 비용은 특히 중저소득층에서 접근성을 제한하는 요인이 될 수 있습니다. 또한, 규제 장벽, 제한적인 상환 정책, 다오믹스 데이터를 임상 워크플로우에 통합하는 복잡성 등이 첨단 진단 솔루션의 보급을 가로막고 있습니다.
이 보고서는 췌장암 진단 세계 시장에 대해 총 매출액, 주요 기업의 시장 점유율 및 순위를 중심으로 지역별, 국가별, 유형별, 용도별 분석을 종합적으로 제시하는 것을 목적으로 합니다.
췌장암 진단 시장의 규모, 추정 및 예측은 2024년을 기준 연도로 하여 2020년에서 2031년까지의 기간의 과거 데이터와 예측 데이터를 포함하는 매출 수익으로 제시되었습니다. 정량적, 정성적 분석을 통해 독자들이 비즈니스/성장 전략 수립, 시장 경쟁 평가, 현재 시장에서의 포지셔닝 분석, 췌장암 진단과 관련된 정보에 입각한 비즈니스 의사결정을 내릴 수 있도록 도와드립니다.
시장 세분화
기업별
- Siemens
- GE Healthcare
- Roche
- Philips Healthcare
- Danaher
- Canon Medical Systems
- Abbott
- Fujifilm
- Qiagen
- Myriad Genetics
- Thermo Fisher Scientific
- Dian Diagnostic
유형별 부문
- 영상 진단
- 종양 바이오마커
- 생검
- 기타
용도별 부문
- 병원
- 진료소
- 기타
지역별
- 북미
- 미국
- 캐나다
- 아시아태평양
- 중국
- 일본
- 한국
- 동남아시아
- 인도
- 호주
- 기타 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 네덜란드
- 북유럽 국가
- 기타 유럽
- 라틴아메리카
- 멕시코
- 브라질
- 기타 라틴아메리카
- 중동 및 아프리카
- 튀르키예
- 사우디아라비아
- 아랍에미리트
- 기타 중동 및 아프리카
자주 묻는 질문
The global market for Pancreatic Cancer Diagnostic was estimated to be worth US$ 6572 million in 2024 and is forecast to a readjusted size of US$ 10690 million by 2031 with a CAGR of 7.3% during the forecast period 2025-2031.
Pancreatic cancer diagnostics refer to the methods and technologies used to detect and identify pancreatic cancer at various stages. These include imaging techniques such as CT, MRI, and endoscopic ultrasound (EUS), as well as molecular diagnostics like biomarker testing (e.g., CA 19-9), genetic testing, and tissue biopsy. Early detection is challenging due to the cancer's asymptomatic nature in early stages, but accurate diagnostic tools are essential for timely treatment and improved survival outcomes.
The pancreatic cancer diagnostic market is driven by the increasing global incidence of pancreatic cancer and the urgent need for early and accurate detection. As pancreatic cancer is often diagnosed at an advanced stage due to its asymptomatic progression, there is growing demand for advanced diagnostic solutions such as molecular biomarkers (e.g., CA 19-9, KRAS mutations), liquid biopsy, next-generation sequencing (NGS), and AI-assisted imaging tools. Government funding for cancer research and the rise of precision oncology initiatives are also encouraging the development and adoption of innovative diagnostic platforms.
Despite technological progress, the market faces significant challenges. Early detection of pancreatic cancer remains difficult due to the lack of specific symptoms and the limited sensitivity and specificity of current biomarkers. High costs associated with advanced diagnostic methods, such as genetic sequencing and imaging, can restrict accessibility, particularly in low- and middle-income regions. Additionally, regulatory hurdles, limited reimbursement policies, and the complexity of integrating multi-omics data into clinical workflows pose barriers to widespread implementation of cutting-edge diagnostic solutions.
This report aims to provide a comprehensive presentation of the global market for Pancreatic Cancer Diagnostic, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Pancreatic Cancer Diagnostic by region & country, by Type, and by Application.
The Pancreatic Cancer Diagnostic market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pancreatic Cancer Diagnostic.
Market Segmentation
By Company
- Siemens
- GE Healthcare
- Roche
- Philips Healthcare
- Danaher
- Canon Medical Systems
- Abbott
- Fujifilm
- Qiagen
- Myriad Genetics
- Thermo Fisher Scientific
- Dian Diagnostic
Segment by Type
- Imaging
- Tumor Biomarker
- Biopsy
- Others
Segment by Application
- Hospitals
- Clinics
- Others
By Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Pancreatic Cancer Diagnostic company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Pancreatic Cancer Diagnostic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Pancreatic Cancer Diagnostic in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
- 1.1 Pancreatic Cancer Diagnostic Product Introduction
- 1.2 Global Pancreatic Cancer Diagnostic Market Size Forecast (2020-2031)
- 1.3 Pancreatic Cancer Diagnostic Market Trends & Drivers
- 1.3.1 Pancreatic Cancer Diagnostic Industry Trends
- 1.3.2 Pancreatic Cancer Diagnostic Market Drivers & Opportunity
- 1.3.3 Pancreatic Cancer Diagnostic Market Challenges
- 1.3.4 Pancreatic Cancer Diagnostic Market Restraints
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered
2 Competitive Analysis by Company
- 2.1 Global Pancreatic Cancer Diagnostic Players Revenue Ranking (2024)
- 2.2 Global Pancreatic Cancer Diagnostic Revenue by Company (2020-2025)
- 2.3 Key Companies Pancreatic Cancer Diagnostic Manufacturing Base Distribution and Headquarters
- 2.4 Key Companies Pancreatic Cancer Diagnostic Product Offered
- 2.5 Key Companies Time to Begin Mass Production of Pancreatic Cancer Diagnostic
- 2.6 Pancreatic Cancer Diagnostic Market Competitive Analysis
- 2.6.1 Pancreatic Cancer Diagnostic Market Concentration Rate (2020-2025)
- 2.6.2 Global 5 and 10 Largest Companies by Pancreatic Cancer Diagnostic Revenue in 2024
- 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pancreatic Cancer Diagnostic as of 2024)
- 2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
- 3.1 Introduction by Type
- 3.1.1 Imaging
- 3.1.2 Tumor Biomarker
- 3.1.3 Biopsy
- 3.1.4 Others
- 3.2 Global Pancreatic Cancer Diagnostic Sales Value by Type
- 3.2.1 Global Pancreatic Cancer Diagnostic Sales Value by Type (2020 VS 2024 VS 2031)
- 3.2.2 Global Pancreatic Cancer Diagnostic Sales Value, by Type (2020-2031)
- 3.2.3 Global Pancreatic Cancer Diagnostic Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
- 4.1 Introduction by Application
- 4.1.1 Hospitals
- 4.1.2 Clinics
- 4.1.3 Others
- 4.2 Global Pancreatic Cancer Diagnostic Sales Value by Application
- 4.2.1 Global Pancreatic Cancer Diagnostic Sales Value by Application (2020 VS 2024 VS 2031)
- 4.2.2 Global Pancreatic Cancer Diagnostic Sales Value, by Application (2020-2031)
- 4.2.3 Global Pancreatic Cancer Diagnostic Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
- 5.1 Global Pancreatic Cancer Diagnostic Sales Value by Region
- 5.1.1 Global Pancreatic Cancer Diagnostic Sales Value by Region: 2020 VS 2024 VS 2031
- 5.1.2 Global Pancreatic Cancer Diagnostic Sales Value by Region (2020-2025)
- 5.1.3 Global Pancreatic Cancer Diagnostic Sales Value by Region (2026-2031)
- 5.1.4 Global Pancreatic Cancer Diagnostic Sales Value by Region (%), (2020-2031)
- 5.2 North America
- 5.2.1 North America Pancreatic Cancer Diagnostic Sales Value, 2020-2031
- 5.2.2 North America Pancreatic Cancer Diagnostic Sales Value by Country (%), 2024 VS 2031
- 5.3 Europe
- 5.3.1 Europe Pancreatic Cancer Diagnostic Sales Value, 2020-2031
- 5.3.2 Europe Pancreatic Cancer Diagnostic Sales Value by Country (%), 2024 VS 2031
- 5.4 Asia Pacific
- 5.4.1 Asia Pacific Pancreatic Cancer Diagnostic Sales Value, 2020-2031
- 5.4.2 Asia Pacific Pancreatic Cancer Diagnostic Sales Value by Region (%), 2024 VS 2031
- 5.5 South America
- 5.5.1 South America Pancreatic Cancer Diagnostic Sales Value, 2020-2031
- 5.5.2 South America Pancreatic Cancer Diagnostic Sales Value by Country (%), 2024 VS 2031
- 5.6 Middle East & Africa
- 5.6.1 Middle East & Africa Pancreatic Cancer Diagnostic Sales Value, 2020-2031
- 5.6.2 Middle East & Africa Pancreatic Cancer Diagnostic Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
- 6.1 Key Countries/Regions Pancreatic Cancer Diagnostic Sales Value Growth Trends, 2020 VS 2024 VS 2031
- 6.2 Key Countries/Regions Pancreatic Cancer Diagnostic Sales Value, 2020-2031
- 6.3 United States
- 6.3.1 United States Pancreatic Cancer Diagnostic Sales Value, 2020-2031
- 6.3.2 United States Pancreatic Cancer Diagnostic Sales Value by Type (%), 2024 VS 2031
- 6.3.3 United States Pancreatic Cancer Diagnostic Sales Value by Application, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Pancreatic Cancer Diagnostic Sales Value, 2020-2031
- 6.4.2 Europe Pancreatic Cancer Diagnostic Sales Value by Type (%), 2024 VS 2031
- 6.4.3 Europe Pancreatic Cancer Diagnostic Sales Value by Application, 2024 VS 2031
- 6.5 China
- 6.5.1 China Pancreatic Cancer Diagnostic Sales Value, 2020-2031
- 6.5.2 China Pancreatic Cancer Diagnostic Sales Value by Type (%), 2024 VS 2031
- 6.5.3 China Pancreatic Cancer Diagnostic Sales Value by Application, 2024 VS 2031
- 6.6 Japan
- 6.6.1 Japan Pancreatic Cancer Diagnostic Sales Value, 2020-2031
- 6.6.2 Japan Pancreatic Cancer Diagnostic Sales Value by Type (%), 2024 VS 2031
- 6.6.3 Japan Pancreatic Cancer Diagnostic Sales Value by Application, 2024 VS 2031
- 6.7 South Korea
- 6.7.1 South Korea Pancreatic Cancer Diagnostic Sales Value, 2020-2031
- 6.7.2 South Korea Pancreatic Cancer Diagnostic Sales Value by Type (%), 2024 VS 2031
- 6.7.3 South Korea Pancreatic Cancer Diagnostic Sales Value by Application, 2024 VS 2031
- 6.8 Southeast Asia
- 6.8.1 Southeast Asia Pancreatic Cancer Diagnostic Sales Value, 2020-2031
- 6.8.2 Southeast Asia Pancreatic Cancer Diagnostic Sales Value by Type (%), 2024 VS 2031
- 6.8.3 Southeast Asia Pancreatic Cancer Diagnostic Sales Value by Application, 2024 VS 2031
- 6.9 India
- 6.9.1 India Pancreatic Cancer Diagnostic Sales Value, 2020-2031
- 6.9.2 India Pancreatic Cancer Diagnostic Sales Value by Type (%), 2024 VS 2031
- 6.9.3 India Pancreatic Cancer Diagnostic Sales Value by Application, 2024 VS 2031
7 Company Profiles
- 7.1 Siemens
- 7.1.1 Siemens Profile
- 7.1.2 Siemens Main Business
- 7.1.3 Siemens Pancreatic Cancer Diagnostic Products, Services and Solutions
- 7.1.4 Siemens Pancreatic Cancer Diagnostic Revenue (US$ Million) & (2020-2025)
- 7.1.5 Siemens Recent Developments
- 7.2 GE Healthcare
- 7.2.1 GE Healthcare Profile
- 7.2.2 GE Healthcare Main Business
- 7.2.3 GE Healthcare Pancreatic Cancer Diagnostic Products, Services and Solutions
- 7.2.4 GE Healthcare Pancreatic Cancer Diagnostic Revenue (US$ Million) & (2020-2025)
- 7.2.5 GE Healthcare Recent Developments
- 7.3 Roche
- 7.3.1 Roche Profile
- 7.3.2 Roche Main Business
- 7.3.3 Roche Pancreatic Cancer Diagnostic Products, Services and Solutions
- 7.3.4 Roche Pancreatic Cancer Diagnostic Revenue (US$ Million) & (2020-2025)
- 7.3.5 Roche Recent Developments
- 7.4 Philips Healthcare
- 7.4.1 Philips Healthcare Profile
- 7.4.2 Philips Healthcare Main Business
- 7.4.3 Philips Healthcare Pancreatic Cancer Diagnostic Products, Services and Solutions
- 7.4.4 Philips Healthcare Pancreatic Cancer Diagnostic Revenue (US$ Million) & (2020-2025)
- 7.4.5 Philips Healthcare Recent Developments
- 7.5 Danaher
- 7.5.1 Danaher Profile
- 7.5.2 Danaher Main Business
- 7.5.3 Danaher Pancreatic Cancer Diagnostic Products, Services and Solutions
- 7.5.4 Danaher Pancreatic Cancer Diagnostic Revenue (US$ Million) & (2020-2025)
- 7.5.5 Danaher Recent Developments
- 7.6 Canon Medical Systems
- 7.6.1 Canon Medical Systems Profile
- 7.6.2 Canon Medical Systems Main Business
- 7.6.3 Canon Medical Systems Pancreatic Cancer Diagnostic Products, Services and Solutions
- 7.6.4 Canon Medical Systems Pancreatic Cancer Diagnostic Revenue (US$ Million) & (2020-2025)
- 7.6.5 Canon Medical Systems Recent Developments
- 7.7 Abbott
- 7.7.1 Abbott Profile
- 7.7.2 Abbott Main Business
- 7.7.3 Abbott Pancreatic Cancer Diagnostic Products, Services and Solutions
- 7.7.4 Abbott Pancreatic Cancer Diagnostic Revenue (US$ Million) & (2020-2025)
- 7.7.5 Abbott Recent Developments
- 7.8 Fujifilm
- 7.8.1 Fujifilm Profile
- 7.8.2 Fujifilm Main Business
- 7.8.3 Fujifilm Pancreatic Cancer Diagnostic Products, Services and Solutions
- 7.8.4 Fujifilm Pancreatic Cancer Diagnostic Revenue (US$ Million) & (2020-2025)
- 7.8.5 Fujifilm Recent Developments
- 7.9 Qiagen
- 7.9.1 Qiagen Profile
- 7.9.2 Qiagen Main Business
- 7.9.3 Qiagen Pancreatic Cancer Diagnostic Products, Services and Solutions
- 7.9.4 Qiagen Pancreatic Cancer Diagnostic Revenue (US$ Million) & (2020-2025)
- 7.9.5 Qiagen Recent Developments
- 7.10 Myriad Genetics
- 7.10.1 Myriad Genetics Profile
- 7.10.2 Myriad Genetics Main Business
- 7.10.3 Myriad Genetics Pancreatic Cancer Diagnostic Products, Services and Solutions
- 7.10.4 Myriad Genetics Pancreatic Cancer Diagnostic Revenue (US$ Million) & (2020-2025)
- 7.10.5 Myriad Genetics Recent Developments
- 7.11 Thermo Fisher Scientific
- 7.11.1 Thermo Fisher Scientific Profile
- 7.11.2 Thermo Fisher Scientific Main Business
- 7.11.3 Thermo Fisher Scientific Pancreatic Cancer Diagnostic Products, Services and Solutions
- 7.11.4 Thermo Fisher Scientific Pancreatic Cancer Diagnostic Revenue (US$ Million) & (2020-2025)
- 7.11.5 Thermo Fisher Scientific Recent Developments
- 7.12 Dian Diagnostic
- 7.12.1 Dian Diagnostic Profile
- 7.12.2 Dian Diagnostic Main Business
- 7.12.3 Dian Diagnostic Pancreatic Cancer Diagnostic Products, Services and Solutions
- 7.12.4 Dian Diagnostic Pancreatic Cancer Diagnostic Revenue (US$ Million) & (2020-2025)
- 7.12.5 Dian Diagnostic Recent Developments
8 Industry Chain Analysis
- 8.1 Pancreatic Cancer Diagnostic Industrial Chain
- 8.2 Pancreatic Cancer Diagnostic Upstream Analysis
- 8.2.1 Key Raw Materials
- 8.2.2 Raw Materials Key Suppliers
- 8.2.3 Manufacturing Cost Structure
- 8.3 Midstream Analysis
- 8.4 Downstream Analysis (Customers Analysis)
- 8.5 Sales Model and Sales Channels
- 8.5.1 Pancreatic Cancer Diagnostic Sales Model
- 8.5.2 Sales Channel
- 8.5.3 Pancreatic Cancer Diagnostic Distributors
9 Research Findings and Conclusion
10 Appendix
- 10.1 Research Methodology
- 10.1.1 Methodology/Research Approach
- 10.1.1.1 Research Programs/Design
- 10.1.1.2 Market Size Estimation
- 10.1.1.3 Market Breakdown and Data Triangulation
- 10.1.2 Data Source
- 10.1.2.1 Secondary Sources
- 10.1.2.2 Primary Sources
- 10.1.1 Methodology/Research Approach
- 10.2 Author Details
- 10.3 Disclaimer
